Hologic, Inc. (NASDAQ:HOLX) – Analysts at SVB Leerink raised their FY2020 earnings per share (EPS) estimates for Hologic in a research report issued to clients and investors on Monday, October 12th. SVB Leerink analyst R. Newitter now forecasts that the medical equipment provider will post earnings per share of $3.31 for the year, up from their previous forecast of $2.94. SVB Leerink has a “Outperform” rating and a $80.00 price objective on the stock. SVB Leerink also issued estimates for Hologic’s Q4 2020 earnings at $1.39 EPS, Q1 2021 earnings at $1.21 EPS, FY2021 earnings at $4.26 EPS and FY2022 earnings at $3.65 EPS. Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.37. The company had revenue of $822.90 million for the quarter, compared to analyst estimates of $622.96 million. Hologic had a return on equity of 31.40% and a net margin of 20.03%. The firm’s revenue for the quarter was down 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 earnings per share.
HOLX has been the topic of several other research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $78.00 price target on shares of Hologic in a research note on Wednesday, August 26th. Morgan Stanley upped their price target on Hologic from $55.00 to $68.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Wells Fargo & Company upped their price target on Hologic from $63.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Cowen raised Hologic from a “market perform” rating to an “outperform” rating and set a $64.00 price target on the stock in a research note on Tuesday, June 30th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $84.00 price target (up previously from $63.00) on shares of Hologic in a research note on Wednesday, July 29th. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $67.36.
Jeff Brown is a member of the U.S. Chamber of Digital Commerce…
And has been asked to share his expertise with officials at the highest level of our national defense and intelligence communities.
Today, he’s issuing a special warning to Mr. Trump.
Shares of Hologic stock opened at $67.67 on Wednesday. Hologic has a 52 week low of $26.49 and a 52 week high of $73.63. The business’s fifty day simple moving average is $63.53 and its 200-day simple moving average is $56.14. The firm has a market cap of $17.53 billion, a PE ratio of 27.40, a price-to-earnings-growth ratio of 0.96 and a beta of 1.34. The company has a quick ratio of 1.17, a current ratio of 1.47 and a debt-to-equity ratio of 1.22.
In other Hologic news, insider Benjamin Jordan Cohn sold 4,924 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $71.24, for a total transaction of $350,785.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.00% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. North Star Investment Management Corp. increased its holdings in Hologic by 37.5% during the 3rd quarter. North Star Investment Management Corp. now owns 550 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 150 shares during the period. Riggs Asset Managment Co. Inc. increased its holdings in Hologic by 230.3% during the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 6,870 shares of the medical equipment provider’s stock worth $179,000 after purchasing an additional 4,790 shares during the period. Envestnet Asset Management Inc. increased its holdings in Hologic by 9.1% during the 3rd quarter. Envestnet Asset Management Inc. now owns 44,423 shares of the medical equipment provider’s stock worth $2,953,000 after purchasing an additional 3,713 shares during the period. Hall Laurie J Trustee purchased a new stake in Hologic during the 3rd quarter worth about $105,000. Finally, Exane Derivatives increased its holdings in Hologic by 5.6% during the 3rd quarter. Exane Derivatives now owns 7,852 shares of the medical equipment provider’s stock worth $522,000 after purchasing an additional 416 shares during the period. Institutional investors own 93.69% of the company’s stock.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops,…
Read More: Equities Analysts Set Expectations for Hologic, Inc.’s FY2020 Earnings